Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report

por Sarfaty, Michal, Moore, Assaf, Dudnik, Elizabeth, Peled, Nir
Publicado 2017

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

por Suidan, Anna May, Roisman, Laila, Belilovski Rozenblum, Anna, Ilouze, Maya, Dudnik, Elizabeth, Zer, Alona, Peled, Nir
Publicado 2019

Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Primary Lung Cancer in Recipients of Lung Transplant

por Moore, Assaf, Kramer, Mordechai R., Rosengarten, Dror, Shtraichman, Osnat, Zer, Alona, Dudnik, Elizabeth, Korzets, Yasmin, Allen, Aaron M.
Publicado 2020

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

por Sternschuss, Michal, Peled, Nir, Allen, Aaron M., Dudnik, Elizabeth, Rotem, Ofer, Kurman, Noga, Gal, Omer, Reches, Hiba, Zer, Alona
Publicado 2020

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

por Landman, Yosef, Jacobi, Oded, Kurman, Noga, Yariv, Orly, Peretz, Idit, Rotem, Ofer, Dudnik, Elizabeth, Zer, Alona, Allen, Aaron M.
Publicado 2021

Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma

por Simon, Michael, Shochat, Tzippy, Peled, Nir, Zer, Alona, Kramer, Mordechai R., Eldan, Orit, Saute, Milton, Dudnik, Elizabeth R., Allen, Aaron M.
Publicado 2018

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course

por Tschernichovsky, Roi, Averbuch, Itamar, Goldstein, Daniel Alex, Mutai, Raz, Dudnik, Elizabeth, Rotem, Ofer, Laufer-Geva, Smadar, Peled, Nir, Goldberg, Yael, Zer, Alona
Publicado 2023

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study

por Icht, Oded, Leader, Avi, Batat, Erez, Yosef, Lilach, Shochat, Tzippy, Goldstein, Daniel A, Dudnik, Elizabeth, Spectre, Galia, Raanani, Pia, Hammerman, Ariel, Zer, Alona
Publicado 2023

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

por Gal, Omer, Dudnik, Elizabeth, Rotem, Ofer, Finkel, Inbar, Peretz, Idit, Zer, Alona, Mandel, Jacob, Amiel, Alexandra, Siegal, Tali, Bar, Jair, Lobachov, Anastasiya, Yust, Shlomit
Publicado 2020

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

por Dudnik, Elizabeth, Bar, Jair, Moore, Assaf, Gottfried, Teodor, Moskovitz, Mor, Dudnik, Julia, Shochat, Tzippy, Allen, Aaron M., Zer, Alona, Rotem, Ofer, Peled, Nir, Urban, Damien
Publicado 2021

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)

por Addeo, Alfredo, Hochmair, Maximilian, Janzic, Urska, Dudnik, Elizabeth, Charpidou, Andriani, Płużański, Adam, Ciuleanu, Tudor, Donev, Ivan Shterev, Elbaz, Judith, Aarøe, Jørgen, Ott, René, Peled, Nir
Publicado 2021

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world da...

por Dudnik, Elizabeth, Moskovitz, Mor, Rottenberg, Yakir, Lobachov, Anastasiya, Mandelboim, Rinat, Shochat, Tzippy, Urban, Damien, Wollner, Mira, Nechushtan, Hovav, Rotem, Ofer, Zer, Alona, Daher, Sameh, Bar, Jair
Publicado 2021

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience

por Moore, Assaf, Bar, Yael, Maurice-Dror, Corinne, Finkel, Inbar, Goldvaser, Hadar, Dudnik, Elizabeth, Goldstein, Daniel A., Gordon, Noa, Billan, Salem, Gutfeld, Orit, Wolf, Ido, Popovtzer, Aron
Publicado 2021

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Ad...

por Raphael, Ari, Dudnik, Elizabeth, Hershkovitz, Dov, Jain, Suyog, Olsen, Steve, Soussan-Gutman, Lior, Ben-Shitrit, Taly, Dvir, Addie, Nechushtan, Hovav, Peled, Nir, Onn, Amir, Agbarya, Abed
Publicado 2022

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the l...

por Averbuch, Itamar, Tschernichovsky, Roi, Icht, Oded, Goldstein, Daniel A., Mutai, Raz, Dudnik, Elizabeth, Rotem, Ofer, Peled, Nir, Allen, Aaron M., Laufer‐Geva, Smadar, Goldberg, Yael, Zer, Alona
Publicado 2023

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

por Dudnik, Elizabeth, Kareff, Samuel, Moskovitz, Mor, Kim, Chul, Liu, Stephen V, Lobachov, Anastasiya, Gottfried, Teodor, Urban, Damien, Zer, Alona, Rotem, Ofer, Onn, Amir, Wollner, Mira, Bar, Jair
Publicado 2021

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

por Daher, Sameh, Lawrence, Yaacov R., Dudnik, Elizabeth, Hanovich, Ekaterina, Urban, Damien, Peled, Nir, Navon, Rossie, Leibowitz, Raya, Hammerman, Ariel, Battat, Erez, Gottfried, Teodor, Onn, Amir, Bar, Jair
Publicado 2021

Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy

por Rotem, Ofer, Zer, Alona, Yosef, Lilach, Beery, Einat, Goldvaser, Hadar, Gutkin, Anna, Levin, Ron, Dudnik, Elizabeth, Berger, Tamar, Feinmesser, Meora, Levy-Barda, Adva, Lahav, Meir, Raanani, Pia, Uziel, Orit
Publicado 2023

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

por Kian, Waleed, Christopoulos, Petros, Remilah, Areen A., Levison, Esther, Dudnik, Elizabeth, Shalata, Walid, Krayim, Bilal, Marei, Ranin, Yakobson, Alexander, Faehling, Martin, Kahala, Dolev, Sara Granot, Inbal, Levitas, Dina, Peled, Nir, Roisman, Laila C.
Publicado 2022

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

por Moskovitz, Mor, Dudnik, Elizabeth, Shamai, Sivan, Rotenberg, Yakir, Popovich-Hadari, Noa, Wollner, Mira, Zer, Alona, Gottfried, Maya, Mishaeli, Moshe, Rosenberg, Shoshana Keren, Onn, Amir, Merimsky, Ofer, Urban, Damien, Peled, Nir, Maimon, Natalie, Bar, Jair
Publicado 2022